Evogene (NASDAQ:EVGN) Issues Quarterly Earnings Results

Evogene (NASDAQ:EVGN) announced its earnings results on Thursday. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78, Zacks reports. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter in the previous year, the firm posted ($1.30) EPS.

Evogene Trading Up 1.4 %

Evogene stock traded up $0.02 during mid-day trading on Thursday, hitting $1.43. The company had a trading volume of 27,796 shares, compared to its average volume of 89,101. Evogene has a 12 month low of $1.20 and a 12 month high of $10.00. The company has a market capitalization of $7.69 million, a PE ratio of -0.32 and a beta of 1.29. The stock’s 50 day moving average price is $1.59 and its two-hundred day moving average price is $2.09.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Evogene in a research note on Sunday. They set a “sell” rating on the stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.